Mizuho analyst Uy Ear lowered the firm’s price target on Relmada Therapeutics to $25 from $26 and keeps a Buy rating on the shares post the Q2 report. . It was “generally a quiet quarter” as the company advances on the Phase 3 clinical plan for REL-1017, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RLMD:
- Relmada Therapeutics reports Q2 EPS (84c), consensus (90c)
- Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Relmada Therapeutics Inc (RLMD) Q2 Earnings Cheat Sheet
- Here’s What You Missed in Cannabis This Week
- Rising High: Exclusive talk with biotech company Tryp Therapeutics